Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022
Los Angeles, May 19, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces a forthcoming presentation by scientific founder Dr. Caius Radu at the Los Angeles Bioscience Ecosystem Summit 2022 (“LABEST”).
Title: Development of a first-in-class/first-in-human inhibitor of deoxycytidine kinase with cancer and autoimmune disease indications
Location: Main Ballroom, Luskin Conference Center
Date: Thursday, May 26, 2022 at 10AM
Track: UCLA Professor Spotlight
Dr. Radu is a Professor in the Departments of Molecular and Medical Pharmacology and Surgery at the University of California Los Angeles (UCLA). He also serves as a Vice Chairman of the Department of Molecular and Medical Pharmacology, Co-Director of the Cancer Molecular Imaging, Nanotechnology, and Theranostics Research Program at the UCLA Jonsson Comprehensive Cancer Center, and Chairman of the Trethera Scientific Advisory Board.
LABEST 2022 is the premier showcase for bioscience innovation in Los Angeles County and is produced by the UCLA Technology Development Group. It is intended to promote awareness of the growing life science entrepreneurial ecosystem in Los Angeles and to foster partnerships with the biotechnology and life science industry.
TRE-515 is an orally delivered therapeutic engineered to inhibit deoxycytidine kinase (“dCK”), the key enzyme in the nucleoside salvage pathway. A common characteristic of solid tumors and autoimmune diseases is that they require elevated nucleotide levels to support abnormal and accelerated cell division. In contrast, dCK activity is highly restricted in healthy adult human cells. Mediated by the rate limiting kinase, dCK, the nucleoside salvage pathway plays a pivotal role in rapid cell proliferation of cancer cells and aberrant activated lymphocytes, suggesting dCK as a potential therapeutic target.
Trethera is a clinical stage privately held biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera’s innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule twice designated by the FDA as an Orphan Drug. TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth. Certain autoimmune diseases might also respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination, to precisely target a metabolic vulnerability of cancer or autoimmune diseases that will transform outcomes for patients.
For more information, please visit us at trethera.com.
Note on Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. Trethera intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.